Replies to post #427309 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

The original trial design would have been confounded by pseudoprogression.

You have been posting on this board for years so you know that.

Obviously you are trying to mislead others.

[flipper44]

You must be new here. Dr. Liau and Dr. Bosch have stated that deciphering pseudoprogression from true progression can make getting valid results challenging and, in some cases, psPD wreaks havoc on clinical trial studies. You must have not been here when Dr. Liau grand round videos covered how pseudoprogression works in her practice after treatment with DCVax-l. That’s ok, you are new. You wouldn’t know some of the reasons they elected to change endpoints in order to minimize risk. You must not know that the world changed the definition of GBM to include about 90% of the patients it used to include, and you must not know that these remainining patients fit the profile of those more likely to respond to DCVax-l. You must not know we get one crack at TLD.